41 research outputs found
Effectiveness and safety of orally administered immunotherapy for food allergies: a systematic review and meta-analysis
The aim of using oral and sublingual immunotherapy with food allergies is to enable the safe consumption of foods containing these aller-
gens in patients with food allergies. In the present study, a systematic review of intervention studies was undertaken; this involved the
searching of eleven international databases for controlled clinical trials. We identified 1152 potentially relevant papers, from which we
selected twenty-two reports of twenty-one eligible trials (i.e. eighteen randomised controlled trials and three controlled clinical trials).
The meta-analysis revealed a substantially lower risk of reactions to the relevant food allergen in those receiving orally administered immu-
notherapy (risk ratios (RR) 0·21, 95 % CI 0·12, 0·38). The meta-analysis of immunological data demonstrated that skin prick test responses to
the relevant food allergen significantly decreased with immunotherapy (mean difference
2
2·96 mm, 95 % CI
2
4·48,
2
1·45), while aller-
gen-specific IgG4 levels increased by an average of 19·9 (95 % CI 17·1, 22·6)
m
g/ml. Sensitivity analyses excluding studies at the highest risk
of bias and subgroup analyses in relation to specific food allergens and treatment approaches generated comparable summary estimates of
effectiveness and immunological changes. Pooling of the safety data revealed an increased risk of local (i.e. minor oropharyngeal/gastro-
intestinal) adverse reactions with immunotherapy (RR 1·47, 95 % CI 1·11, 1·95); there was a non-significant increased average risk of
systemic adverse reactions with immunotherapy (RR 1·08, 95 % CI 0·97, 1·19). There is strong evidence that orally administered immu-
notherapy can induce immunomodulatory changes and thereby promote desensitisation to a range of foods. However, given the paucity
of evidence on longer-term safety, effectiveness and cost-effectiveness, orally administered immunotherapy should not be used outside
experimental conditions presently
Use of serial qualitative interviews to understand patients’ evolving experiences and needs
Interviewing patients over the course of their illness can give a much better picture of their experience than single interviews, but the approach is rarely used. Scott Murray and colleagues explain how to get the most from it
Use of multiperspective qualitative interviews to understand patients’ and carers’ beliefs, experiences, and needs
A better understanding of the needs of patients and their carers can help improve services. Marilyn Kendall and colleagues describe how to conduct multiperspective studies
Chemical Similarity and Threshold of Toxicological Concern (TTC) Approaches: Report of an ECB Workshop held in Ispra, November 2005
There are many national, regional and international programmes – either regulatory or voluntary – to assess the hazards or risks of chemical substances to humans and the environment. The first step in making a hazard assessment of a chemical is to ensure that there is adequate information on each of the endpoints. If adequate information is not available then additional data is needed to complete the dataset for this substance. For reasons of resources and animal welfare, it is important to limit the number of tests that have to be conducted, where this is scientifically justifiable. One approach is to consider closely related chemicals as a group, or chemical category, rather than as individual chemicals. In a category approach, data for chemicals and endpoints that have been already tested are used to estimate the hazard for untested chemicals and endpoints. Categories of chemicals are selected on the basis of similarities in biological activity which is associated with a common underlying mechanism of action.
A homologous series of chemicals exhibiting a coherent trend in biological activity can be rationalised on the basis of a constant change in structure. This type of grouping is relatively straightforward. The challenge lies in identifying the relevant chemical structural and physicochemical characteristics that enable more sophisticated groupings to be made on the basis of similarity in biological activity and hence purported mechanism of action. Linking two chemicals together and rationalising their similarity with reference to one or more endpoints has been very much carried out on an ad hoc basis. Even with larger groups, the process and approach is ad hoc and based on expert judgement. There still appears to be very little guidance about the tools and approaches for grouping chemicals systematically.
In November 2005, the ECB Workshop on Chemical Similarity and Thresholds of Toxicological Concern (TTC) Approaches was convened to identify the available approaches that currently exist to encode similarity and how these can be used to facilitate the grouping of chemicals. This report aims to capture the main themes that were discussed.
In particular, it outlines a number of different approaches that can facilitate the formation of chemical groupings in terms of the context under consideration and the likely information that would be required. Grouping methods were divided into one of four classes – knowledge-based, analogue-based, unsupervised, and supervised. A flowchart was constructed to attempt to capture a possible work flow to highlight where and how these approaches might be best applied.JRC.I.3-Toxicology and chemical substance
Financial considerations in the conduct of multi-centre randomised controlled trials: evidence from a qualitative study.
National Coordinating Centre for Research Methodology; Medical Research Council, UK Department of Health; Chief Scientist OfficeNot peer reviewedPublisher PD
MIRO-1 Determines Mitochondrial Shape Transition upon GPCR Activation and Ca^(2+) Stress
Mitochondria shape cytosolic calcium ([Ca^(2+)]_c) transients and utilize the mitochondrial Ca_2^+ ([Ca^(2+)]_m) in exchange for bioenergetics output. Conversely, dysregulated [Ca^(2+)]_c causes [Ca^(2+)]_m overload and induces permeability transition pore and cell death. Ablation of MCU-mediated Ca^(2+) uptake exhibited elevated [Ca^(2+)]_c and failed to prevent stress-induced cell death. The mechanisms for these effects remain elusive. Here, we report that mitochondria undergo a cytosolic Ca^(2+)-induced shape change that is distinct from mitochondrial fission and swelling. [Ca^(2+)]_c elevation, but not MCU-mediated Ca^(2+) uptake, appears to be essential for the process we term mitochondrial shape transition (MiST). MiST is mediated by the mitochondrial protein Miro1 through its EF-hand domain 1 in multiple cell types. Moreover, Ca^(2+)-dependent disruption of Miro1/KIF5B/tubulin complex is determined by Miro1 EF1 domain. Functionally, Miro1-dependent MiST is essential for autophagy/mitophagy that is attenuated in Miro1 EF1 mutants. Thus, Miro1 is a cytosolic Ca^(2+) sensor that decodes metazoan Ca^(2+) signals as MiST
MIRO-1 Determines Mitochondrial Shape Transition upon GPCR Activation and Ca^(2+) Stress
Mitochondria shape cytosolic calcium ([Ca^(2+)]_c) transients and utilize the mitochondrial Ca_2^+ ([Ca^(2+)]_m) in exchange for bioenergetics output. Conversely, dysregulated [Ca^(2+)]_c causes [Ca^(2+)]_m overload and induces permeability transition pore and cell death. Ablation of MCU-mediated Ca^(2+) uptake exhibited elevated [Ca^(2+)]_c and failed to prevent stress-induced cell death. The mechanisms for these effects remain elusive. Here, we report that mitochondria undergo a cytosolic Ca^(2+)-induced shape change that is distinct from mitochondrial fission and swelling. [Ca^(2+)]_c elevation, but not MCU-mediated Ca^(2+) uptake, appears to be essential for the process we term mitochondrial shape transition (MiST). MiST is mediated by the mitochondrial protein Miro1 through its EF-hand domain 1 in multiple cell types. Moreover, Ca^(2+)-dependent disruption of Miro1/KIF5B/tubulin complex is determined by Miro1 EF1 domain. Functionally, Miro1-dependent MiST is essential for autophagy/mitophagy that is attenuated in Miro1 EF1 mutants. Thus, Miro1 is a cytosolic Ca^(2+) sensor that decodes metazoan Ca^(2+) signals as MiST
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Background:
A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials.
Methods:
This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674.
Findings:
Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation.
Interpretation:
ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.
Funding:
UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D’Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca
Impact of Optimized Breastfeeding on the Costs of Necrotizing Enterocolitis in Extremely Low Birthweight Infants
To estimate risk of NEC for ELBW infants as a function of preterm formula and maternal milk (MM) intake and calculate the impact of suboptimal feeding on NEC incidence and costs